About
Technology
Issues
FAQ
Links
Official Page
Efficacy and safety of ixekizumab treatment for Japanese patients with moderate to severe plaque psoriasis, erythrodermic psoriasis and generalized pustular psoriasis: Results from a 52‐week, open‐label, phase 3 study (
UNCOVER
‐J)
Distribution of the number of citations over years.
site/software ©
exaly
; All materials licenced under
CC by-SA
.